Table Graph
      published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMARIPOSA, 2021 1.43 [0.42; 4.87] Rashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 0.35 [0.17; 0.74] 1.11[0.27; 4.56]MARIPOSA, 2021, Rashad, 2021, Rashad, 2021387%395seriousnot evaluable deathsdetailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable hospital dischargedetailed resultsMARIPOSA, 2021 0.88 [0.55; 1.40] 0.88[0.55; 1.40]MARIPOSA, 202110%NAnot evaluable mechanical ventilationdetailed resultsMARIPOSA, 2021 0.88 [0.37; 2.10] 0.88[0.37; 2.10]MARIPOSA, 202110%97NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-06 17:30 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons